New hope for tough cancers: early trial tests ZG006 drug
NCT ID NCT05978284
Summary
This early-stage study is testing a new drug called ZG006 for people with advanced small cell lung cancer or neuroendocrine carcinoma who have no standard treatments left or cannot tolerate them. The main goals are to find a safe dose, check for side effects, and see if the drug helps shrink tumors. It will enroll about 54 adults who meet specific health criteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.